Tag Archives: Warp Drive Bio

← Older posts Newer posts →

With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?

A new biotech has debuted today aiming to make a variety of treatments for deadly liver diseases. The startup, Ambys Medicines, has formed an unusual, broad alliance with Takeda. Some early, wide-ranging partnerships between new biotechs and Big Pharma have fallen apart in the past and have been too limiting for the biotech, but Ambys’s […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, New York top stories, San Diego blog main, San Diego top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?

Bio Roundup: Kite’s CAR-T Approved, Obamacare Fix & Lilly mRNA Deal

Kite Pharma wasn’t expecting a regulatory decision for its non-Hodgkin lymphoma treatment until November, but this week, the company got the FDA’s O.K. The approval of axicabtagene ciloleucel (Yescarta) marks the second time in the two months that the FDA has given the nod to a CAR-T therapy, a treatment made from a patient’s own […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Kite’s CAR-T Approved, Obamacare Fix & Lilly mRNA Deal

Race to Mine Fungi for Drugs Revs up as Verdine’s LifeMine Gets $55M

Can the life sciences industry finally begin to efficiently and systematically exploit the potential treasure trove of drugs hidden in fungi? It seems promising, thanks to cheaper DNA sequencing technologies, artificial intelligence, new academic research, and now the largest funding yet for a startup trying to take on the task. This morning, LifeMine Therapeutics, a […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, San Francisco blog main, San Francisco top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Race to Mine Fungi for Drugs Revs up as Verdine’s LifeMine Gets $55M

Bio Roundup: Fast “Cures,” Trump In Time, CRISPR In Court & More

What a week. The 21st Century Cures Act is now waiting President Obama’s promised signature after easy passage through Congress. President-elect Donald Trump re-stirred the drug-pricing pot with comments in Time Magazine and a reported FDA commissioner candidate who doesn’t seem to think much of the regulatory process. And a trio of judges met to […]

Posted in Boston blog main, Boulder/Denver blog main, Detroit blog main, Indiana blog main, National, National blog main, National top stories, New York blog main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Fast “Cures,” Trump In Time, CRISPR In Court & More

East Coast Biotech Roundup: Intellia, What’s Hot, Cydan, Fog & More

Gene editing was in the news again this week, thanks to Intellia Therapeutics, which looks poised to become the second company developing drugs with CRISPR-Cas9 technology to go public. It wouldn’t be a surprise to see a third, CRISPR Therapeutics, follow suit. That means investors will have a chance to place and hedge their bets […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on East Coast Biotech Roundup: Intellia, What’s Hot, Cydan, Fog & More

With Latest Startup, Harvard’s Verdine Again Aims at Elusive Targets

Harvard University chemical biologist and serial entrepreneur Greg Verdine has spent more than a decade trying to come up with different solutions for one critical problem in biotech: The majority of would-be drug targets are out of reach of existing technologies. That drive has already led to several different companies—among them Aileron Therapeutics, Warp Drive […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, San Diego blog main, San Francisco blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on With Latest Startup, Harvard’s Verdine Again Aims at Elusive Targets

Warp Drive, Surface, Bamboo Cut Deals on Eve of J.P. Morgan

There’s always some last-minute dealmaking on the eve of the annual J.P. Morgan Healthcare Conference in San Francisco, and this year is no exception. Here are a few of the East Coast highlights to cross Xconomy’s radar screen as we gear up for this year’s festivities. —Sanofi and Warp Drive Bio have had a unique […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Warp Drive, Surface, Bamboo Cut Deals on Eve of J.P. Morgan

WaVe, Voyager Get $170M Combined in Biotech’s Latest IPO Tests

Two privately held biotechs in the Boston area priced IPOs on Tuesday with similar estimates about their value. One of them hit its mark, thanks to some help from a few insiders, but the other fell a bit short. WaVe Life Sciences, of Cambridge, MA, priced 6,375,000 shares at $16 apiece, raising $102 million. That’s […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on WaVe, Voyager Get $170M Combined in Biotech’s Latest IPO Tests

Idea Behind Warp Drive’s New Cancer Attack Was Hiding In Plain Sight

[Corrected, 11/12/15, 4:17pm. See below.] The way pharmaceuticals work is often described as keys fitting locks. A drug goes into the body and finds its target because it matches up with a small stretch of biological material within cells or on their surface. But there are all kinds of biological doors which have no locks—no […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, San Francisco blog main, Seattle blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Idea Behind Warp Drive’s New Cancer Attack Was Hiding In Plain Sight

Ex-Blueprint Med CEO Resurfaces With $7.5M to Fight Genetic Blindness

People lose their vision most often because, simply speaking, they grow old. But in rare cases, a genetic defect leads to a blindness in children and teenagers called Stargardt disease. As with many rare diseases, there are no effective treatments for Stargardt.  The Boston startup Vision Medicines hopes to change that. There’s a long way […]

Posted in Boston, Boston blog main, National blog main, National top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Ex-Blueprint Med CEO Resurfaces With $7.5M to Fight Genetic Blindness← Older posts Newer posts →